Lexicon's Clock Slips Again While the HCM Binary Takes Center Stage
ZYNQUISTA resubmission moves to 1Q27, SONATA-HCM becomes the whole equity story, and a preclinical obesity signal adds optionality—but not revenue.
LXRX · Earnings Call · 2026-11-05
The clock slips again
Lexicon's Q3 was less a revenue quarter than a timetable quarter. Revenue was $11.3M, of which $10M was a Novo Nordisk milestone and just $1.2M was INPEFA. The net loss was $14.0M, and cash stood at $183.2M. But the number that matters is the ZYNQUISTA resubmission: it is now guided to 1Q27. Mike Exton put it plainly: “While this process is taking longer than we originally anticipated, we expect to complete the resubmission in the first quarter of 2027.” — Mike Exton, Chief Executive Officer and Director · 2026-11-05 That is a second slip. In August, he had said “we think that the submission could be as early as the end of October, which with a 6-month review would put us nicely in Q2” — Michael Exton, Chief Executive Officer and Director · 2026-08-06. And even then, Craig Granowitz was already conceding that “it's just taking them more time” — Craig Granowitz, Senior Vice President and Chief Medical Officer · 2026-08-06. The culprit is STENO, an investigator-initiated Danish type 1 diabetes study. The explanation is administrative, not safety: cleaning an academic database to FDA review standards, GDPR consent changes, financial disclosures. The DKA rate is about one event per 100 patient-years, comparable to standard of care. But investors discount administrative delays too. The stock is down 31% over 90 days and 35% from its August peak; an analyst initiation at $8 in late September did not arrest the slide.
this was an investigator-initiated trial that was set up in a manner that was never designed to do the level of oversight and intensive monitoring that you would see, like we see in SONATA-HCM or any of the other regulatory labeling studies.
That is a fair explanation, but it is also the second time investors have heard it. The first delay moved the goalposts from an approval in 2026 to a resubmission in late 2026. This one pushes the filing into 1Q27, which likely pushes any approval into the second half of 2027. In a small-cap biotech, that is not a calendar detail—it is a financing and credibility event.
HCM is now the whole story
The Q&A barely dwelt on type 1 diabetes. Analysts spent their time on SONATA-HCM baseline characteristics. That is the tell: the equity story has migrated from a near-term T1D resubmission to a binary HCM readout. Enrollment is complete at 542 patients—440 non-obstructive, 102 obstructive—above the 500 target. Overall baseline KCCQ was 59; in obstructive HCM it was 55, versus 75 in SEQUOIA. Management argues the lower baseline leaves more room for a delta. They also held the statistical line: the primary endpoint remains KCCQ in the overall population, and the key secondary remains NYHA overall. Craig Granowitz: “the primary endpoint of KCCQ in the overall population is going to stay the primary.” — Craig Granowitz, Senior Vice President and Chief Medical Officer · 2026-11-05 That resolves a prior analyst concern about reordering endpoints to salvage a subgroup, but it also means the 81% non-obstructive mix has to carry the overall result. If the obstructive cohort is directionally consistent, management thinks FDA will grant a broad label. If not, label risk. Top-line is still expected 1Q27.
The baseline also tells us how pragmatic this trial is. About 80% of patients were on beta blockers; 50 were on a calcium channel blocker and 49 were on a cardiac myosin inhibitor—roughly 9% each. That CMI cohort is too small to make SONATA a clean combination study, but it does reflect real-world cardiology. Management says it powered for a 4–5 point KCCQ difference and over-enrolled to protect power. The risk is not statistical; it is phenotypic. A 102-patient obstructive cohort may be too small to stand alone if the overall result is driven by non-obstructive patients, and FDA will look at the interaction P-value. Management's heart-failure precedent—HFrEF and HFpEF in one label—is the argument for broad approval, but it is not a guarantee.
The obesity option
Pilavapadin, the AAK1 inhibitor already Phase III-ready in pain, now has preclinical obesity data: 14% weight loss as monotherapy at 10 mg/kg after 28 days, and 31% in combination with semaglutide versus 25% for semaglutide alone. That is a new weight loss angle, and it explains why body weight is suddenly a top keyword for Lexicon. Mike said they have discussed it with Novo: “We have had the chance to discuss this with a couple of people within Novo, not the broader team.” — Mike Exton, Chief Executive Officer and Director · 2026-11-05 It is a call option, not a catalyst. The data are preclinical, there is no human obesity trial, and the obesity tape is crowded. Still, it gives Lexicon a second shot on goal in obesity beyond LX9851 and could support partnering. But it does not change the 1Q27 binary risk.
What the balance sheet buys
Cash was $183.2M versus $125.2M at year-end, and operating expense guidance was maintained at $100–110M. R&D was $16.2M; SG&A was $9.5M. R&D expense has been cut by 59% over ten years. That runway matters because two binary events now collide in 1Q27. If SONATA hits, the ZYNQUISTA slip becomes a footnote. If SONATA misses, the delay becomes the whole story. Revenue quality is thin: $10M of the $11.3M was a milestone, and INPEFA product sales were only $1.2M. That is not a commercial story; it is a licensing and pipeline story. At a $716M market cap, the equity is a levered bet on one readout. The market has already voted: down 31% in 90 days, with a bullish initiation failing to hold. Lexicon is cheaper, but it is not less binary.